Athena Capital Advisors LLC bought a new position in shares of Astrazeneca PLC (NYSE:AZN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 162,600 shares of the company’s stock, valued at approximately $5,509,000. Astrazeneca accounts for about 1.4% of Athena Capital Advisors LLC’s holdings, making the stock its 14th largest holding.

Several other hedge funds have also recently added to or reduced their stakes in AZN. WFG Advisors LP boosted its holdings in Astrazeneca by 36.0% in the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after purchasing an additional 984 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its holdings in Astrazeneca by 71.2% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after purchasing an additional 1,769 shares in the last quarter. Quadrant Capital Group LLC boosted its holdings in Astrazeneca by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after purchasing an additional 846 shares in the last quarter. Westport Asset Management Inc. acquired a new position in Astrazeneca in the second quarter valued at approximately $170,000. Finally, First Interstate Bank boosted its holdings in Astrazeneca by 10.3% in the second quarter. First Interstate Bank now owns 5,127 shares of the company’s stock valued at $175,000 after purchasing an additional 480 shares in the last quarter. Hedge funds and other institutional investors own 14.75% of the company’s stock.

A number of equities analysts recently issued reports on AZN shares. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, August 9th. Investec raised Astrazeneca from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Argus reaffirmed a “buy” rating and issued a $35.00 price target on shares of Astrazeneca in a report on Friday, September 1st. Natixis raised Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, September 6th. Finally, BMO Capital Markets started coverage on Astrazeneca in a report on Wednesday, September 6th. They issued an “outperform” rating and a $38.00 price target for the company. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $34.20.

Shares of Astrazeneca PLC (NYSE AZN) opened at $32.17 on Tuesday. The firm has a market capitalization of $83,172.78, a P/E ratio of 7.84, a PEG ratio of 3.19 and a beta of 0.72. Astrazeneca PLC has a fifty-two week low of $25.55 and a fifty-two week high of $35.60. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The business had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. Astrazeneca had a return on equity of 34.02% and a net margin of 15.90%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.32 earnings per share. sell-side analysts predict that Astrazeneca PLC will post 1.87 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Athena Capital Advisors LLC Buys New Position in Astrazeneca PLC (AZN)” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://theolympiareport.com/2017/12/05/athena-capital-advisors-llc-buys-new-position-in-astrazeneca-plc-azn.html.

Astrazeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for Astrazeneca (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.